ONK Therapeutics

ONK Therapeutics is a private, preclinical-stage biotech based in Galway, Ireland, pioneering an engineered NK cell therapy platform. The company's core strategy involves genetic modifications, including a foundational CISH knockout, to enhance the potency, homing, and durability of off-the-shelf NK cells. While still in preclinical development, ONK is actively forming research partnerships to advance its pipeline and platform, targeting a significant opportunity in both hematological malignancies and solid tumors.

Proprietary platform for engineering off-the-shelf natural killer (NK) cells. Core features include CISH gene knockout to enhance persistence and function, dual-targeting strategies to mitigate antigen escape, and genetic modifications to overcome tumor microenvironment suppression and improve homing.

ONK operates in a highly competitive field with companies like Nkarta, Fate Therapeutics, Affimed, and Dragonfly Therapeutics, as well as large pharma partners, all developing NK cell-based therapies. Differentiation hinges on the efficacy of its specific engineering approach (CISH knockout + dual-targeting) and its ability to demonstrate superior persistence and solid tumor activity.